Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

311 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Etanercept in spondyloarthropathies. Part I: current evidence of efficacy.
Palazzi C, D'Angelo S, Cantini F, Lubrano E, Marchesoni A, Mathieu A, Salvarani C, Scarpa R, Spadaro A, Olivieri I. Palazzi C, et al. Among authors: spadaro a. Clin Exp Rheumatol. 2011 Sep-Oct;29(5):858-64. Epub 2011 Oct 31. Clin Exp Rheumatol. 2011. PMID: 22041180 Review.
Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology.
Salvarani C, Pipitone N, Marchesoni A, Cantini F, Cauli A, Lubrano E, Punzi L, Scarpa R, Spadaro A, Matucci-Cerinic M, Olivieri I; Italian Society for Rheumatology. Salvarani C, et al. Among authors: spadaro a. Clin Exp Rheumatol. 2011 May-Jun;29(3 Suppl 66):S28-41. Epub 2011 Jul 26. Clin Exp Rheumatol. 2011. PMID: 21906425 Review.
Etanercept in psoriatic arthritis.
Spadaro A, Lubrano E, Ferrara N, Scarpa R. Spadaro A, et al. J Rheumatol Suppl. 2012 Jul;89:74-6. doi: 10.3899/jrheum.120250. J Rheumatol Suppl. 2012. PMID: 22751599 Review.
Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: the extension of the Psoriatic Arthritis Cost Evaluation (PACE) study.
Olivieri I, Cortesi PA, de Portu S, Salvarani C, Cauli A, Lubrano E, Spadaro A, Cantini F, Ciampichini R, Cutro MS, Mathieu A, Matucci-Cerinic M, Punzi L, Scarpa R, Mantovani LG; PACE Working Group. Olivieri I, et al. Among authors: spadaro a. Clin Exp Rheumatol. 2016 Jan-Feb;34(1):68-75. Epub 2015 Dec 3. Clin Exp Rheumatol. 2016. PMID: 26633622 Clinical Trial.
Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study.
Spadaro A, Punzi L, Marchesoni A, Lubrano E, Mathieu A, Cantini F, Olivieri I, Salvarani C, Scarpa R, Scrivo R, Ramonda R, Porru G, D'Angelo S, Catanoso M, Atteno M, Valesini G. Spadaro A, et al. Rheumatology (Oxford). 2010 Jun;49(6):1107-11. doi: 10.1093/rheumatology/keq008. Epub 2010 Mar 11. Rheumatology (Oxford). 2010. PMID: 20223813
Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study.
Cauli A, Gladman DD, Mathieu A, Olivieri I, Porru G, Tak PP, Sardu C, Ujfalussy I, Scarpa R, Marchesoni A, Taylor WJ, Spadaro A, Fernàndez-Sueiro JL, Salvarani C, Kalden JR, Lubrano E, Carneiro S, Desiati F, Flynn JA, D'Angelo S, Vacca A, VAN Kuijk AW, Catanoso MG, Gruenke M, Peluso R, Parsons WJ, Ferrara N, Contu P, Helliwell PS, Mease PJ; GRAPPA 3PPsA Study Group. Cauli A, et al. Among authors: spadaro a. J Rheumatol. 2011 May;38(5):898-903. doi: 10.3899/jrheum.100857. Epub 2011 Feb 15. J Rheumatol. 2011. PMID: 21324965 Clinical Trial.
311 results